Evaxion Biotech is committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone and applying the relevant accessibility standards. We strive to meet the level AA criteria of the World Wide Web Consortium Web Accessibility Initiative (WCAG WAI) 2.1 guidelines.

This site has been built using code compliant with W3C standards for HTML and CSS. The site displays correctly in current browsers and using standards compliant HTML/CSS code means any future browsers will also display it correctly.

The Web Content Accessibility Guidelines (WCAG) define requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA. Evaxion Biotech is partially conformant with WCAG 2.1 level AA. Partially conformant means that some parts of the content do not fully conform to the accessibility standard.

The accessibility of Evaxion Biotech is a continual effort. Accessibility standards are built into our design, and style guides and included as part of requirements in our software development and quality assurance pipeline.

Evaxion Biotech assessed the accessibility of this site using the following method(s):

• Self-evaluation: the site was evaluated internally by the company.
• External evaluation: the site was evaluated and checked for accessibility using automated by the external entities.

We welcome your feedback on the accessibility of Evaxion Biotech. Please let us know if you encounter accessibility barriers on our website:

• E-mail: editor@evaxion-biotech.com

We aim to respond to accessibility feedback within 5 business days, and to propose a solution within 10 business days.

This Accessibility Statement is approved by:

Evaxion Biotech

This accessibility statement was generated on October 7nd, 2022.